Applied Finance Capital Management LLC Makes New $265,000 Investment in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Applied Finance Capital Management LLC has made a new investment in BioMarin Pharmaceutical Inc., purchasing 4,825 shares valued at approximately $265,000.
• Multiple institutional investors, including Rise Advisors LLC and Banque Transatlantique SA, have recently adjusted their positions in BioMarin, with institutional ownership at around 98.71%.
• Analysts have varied opinions on BioMarin, with ratings ranging from "strong-buy" to "hold," and a consensus target price set at $93.26.

Applied Finance Capital Management LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,825 shares of the biotechnology company's stock, valued at approximately $265,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new stake in BioMarin Pharmaceutical in the first quarter valued at $30,000. Farther Finance Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after buying an additional 211 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in BioMarin Pharmaceutical in the 2nd quarter valued at $25,000. Brooklyn Investment Group increased its stake in BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 540 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new position in shares of BioMarin Pharmaceutical during the 1st quarter valued at about $71,000. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN opened at $53.29 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $51.56 and a 52-week high of $73.51. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $10.23 billion, a PE ratio of 15.81, a P/E/G ratio of 0.67 and a beta of 0.33. The firm has a 50-day moving average price of $55.66 and a 200 day moving average price of $57.49.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Wall Street Zen downgraded BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Zacks Research lowered shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Raymond James Financial began coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 target price for the company. JPMorgan Chase & Co. lifted their price target on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday, October 9th. Finally, Guggenheim boosted their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Thirteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $93.26.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.